168 related articles for article (PubMed ID: 38396134)
1. Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial.
Carpentier A; Stupp R; Sonabend AM; Dufour H; Chinot O; Mathon B; Ducray F; Guyotat J; Baize N; Menei P; de Groot J; Weinberg JS; Liu BP; Guemas E; Desseaux C; Schmitt C; Bouchoux G; Canney M; Idbaih A
Nat Commun; 2024 Feb; 15(1):1650. PubMed ID: 38396134
[TBL] [Abstract][Full Text] [Related]
2. Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial.
Sonabend AM; Gould A; Amidei C; Ward R; Schmidt KA; Zhang DY; Gomez C; Bebawy JF; Liu BP; Bouchoux G; Desseaux C; Helenowski IB; Lukas RV; Dixit K; Kumthekar P; Arrieta VA; Lesniak MS; Carpentier A; Zhang H; Muzzio M; Canney M; Stupp R
Lancet Oncol; 2023 May; 24(5):509-522. PubMed ID: 37142373
[TBL] [Abstract][Full Text] [Related]
3. Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma.
Idbaih A; Canney M; Belin L; Desseaux C; Vignot A; Bouchoux G; Asquier N; Law-Ye B; Leclercq D; Bissery A; De Rycke Y; Trosch C; Capelle L; Sanson M; Hoang-Xuan K; Dehais C; Houillier C; Laigle-Donadey F; Mathon B; André A; Lafon C; Chapelon JY; Delattre JY; Carpentier A
Clin Cancer Res; 2019 Jul; 25(13):3793-3801. PubMed ID: 30890548
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial of blood-brain barrier disruption by pulsed ultrasound.
Carpentier A; Canney M; Vignot A; Reina V; Beccaria K; Horodyckid C; Karachi C; Leclercq D; Lafon C; Chapelon JY; Capelle L; Cornu P; Sanson M; Hoang-Xuan K; Delattre JY; Idbaih A
Sci Transl Med; 2016 Jun; 8(343):343re2. PubMed ID: 27306666
[TBL] [Abstract][Full Text] [Related]
5. Acoustic feedback enables safe and reliable carboplatin delivery across the blood-brain barrier with a clinical focused ultrasound system and improves survival in a rat glioma model.
McDannold N; Zhang Y; Supko JG; Power C; Sun T; Peng C; Vykhodtseva N; Golby AJ; Reardon DA
Theranostics; 2019; 9(21):6284-6299. PubMed ID: 31534551
[TBL] [Abstract][Full Text] [Related]
6. Safe long-term repeated disruption of the blood-brain barrier using an implantable ultrasound device: a multiparametric study in a primate model.
Horodyckid C; Canney M; Vignot A; Boisgard R; Drier A; Huberfeld G; François C; Prigent A; Santin MD; Adam C; Willer JC; Lafon C; Chapelon JY; Carpentier A
J Neurosurg; 2017 Apr; 126(4):1351-1361. PubMed ID: 27285538
[TBL] [Abstract][Full Text] [Related]
7. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
[TBL] [Abstract][Full Text] [Related]
8. Enhanced brain distribution of carboplatin in a primate model after blood-brain barrier disruption using an implantable ultrasound device.
Goldwirt L; Canney M; Horodyckid C; Poupon J; Mourah S; Vignot A; Chapelon JY; Carpentier A
Cancer Chemother Pharmacol; 2016 Jan; 77(1):211-6. PubMed ID: 26645405
[TBL] [Abstract][Full Text] [Related]
9. A novel implantable catheter system with transcutaneous port for intermittent convection-enhanced delivery of carboplatin for recurrent glioblastoma.
Barua NU; Hopkins K; Woolley M; O'Sullivan S; Harrison R; Edwards RJ; Bienemann AS; Wyatt MJ; Arshad A; Gill SS
Drug Deliv; 2016; 23(1):167-73. PubMed ID: 24786643
[TBL] [Abstract][Full Text] [Related]
10. Focused Ultrasound-Mediated Blood-Brain Barrier Opening Increases Delivery and Efficacy of Etoposide for Glioblastoma Treatment.
Wei HJ; Upadhyayula PS; Pouliopoulos AN; Englander ZK; Zhang X; Jan CI; Guo J; Mela A; Zhang Z; Wang TJC; Bruce JN; Canoll PD; Feldstein NA; Zacharoulis S; Konofagou EE; Wu CC
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):539-550. PubMed ID: 33346092
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease with an implantable ultrasound device.
Epelbaum S; Burgos N; Canney M; Matthews D; Houot M; Santin MD; Desseaux C; Bouchoux G; Stroer S; Martin C; Habert MO; Levy M; Bah A; Martin K; Delatour B; Riche M; Dubois B; Belin L; Carpentier A
Alzheimers Res Ther; 2022 Mar; 14(1):40. PubMed ID: 35260178
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Reardon DA; Desjardins A; Peters KB; Vredenburgh JJ; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Coan A; Threatt S; Friedman AH; Friedman HS
Cancer; 2011 Dec; 117(23):5351-8. PubMed ID: 21590689
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study.
Robins HI; Chang SM; Prados MD; Yung WK; Hess K; Schiff D; Greenberg H; Fink K; Nicolas K; Kuhn JG; Cloughesy T; Junck L; Mehta M
Neuro Oncol; 2002 Apr; 4(2):109-14. PubMed ID: 11916502
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.
Galanis E; Buckner JC; Maurer MJ; Reid JM; Kuffel MJ; Ames MM; Scheithauer BW; Hammack JE; Pipoly G; Kuross SA
Invest New Drugs; 2005 Oct; 23(5):495-503. PubMed ID: 16133802
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
Reardon DA; Desjardins A; Peters KB; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Bulusu A; Threatt S; Friedman AH; Vredenburgh JJ; Friedman HS
J Neurooncol; 2012 Mar; 107(1):155-64. PubMed ID: 21986722
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S; Scambia G; Schettino C; Arenare L; Pisano C; Lombardi D; De Giorgi U; Andreetta C; Cinieri S; De Angelis C; Priolo D; Casanova C; Rosati M; Greco F; Zafarana E; Schiavetto I; Mammoliti S; Cecere SC; Salutari V; Scalone S; Farolfi A; Di Napoli M; Lorusso D; Gargiulo P; Califano D; Russo D; Spina A; De Cecio R; Chiodini P; Perrone F;
Lancet Oncol; 2023 Mar; 24(3):286-296. PubMed ID: 37052965
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
